Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058993 · ClinicalTrials.gov registry record · Phase 1
AMD 3100 for Treatment of Myelokathexis
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01058993: Completed Phase 1 study, sponsored by University of Washington.
NCT01058993 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01058993, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and myelokathexis) syndrome. This is the initial study of this concept and will involve up to 6 patients to receive increasing doses of plerixafor administered subcutaneously or on an alternate day basis. It is unknown if these patients will be highly sensitive to a blockade of CXCR4 activity and release more white blood cells than normal volunteers or cancer patients given the same dose of this drug. Therefore doses will begin at a level 12 fold less than currently used to mobilize stem cells and will be increased stepwise to achieve an acceptable circulating level of neutrophils.
Primary Outcome
Effectiveness of drug based on increases of blood neutrophil counts to greater than 2.0 x 10\^9 per liter
Interventions
- DRUG AMD3100 or plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
What the finished NCT01058993 record still lists
NCT01058993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which AMD3100 or plerixafor is the first listed.
NCT01058993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01058993 about?
NCT01058993 is a clinical study titled "AMD 3100 for Treatment of Myelokathexis". This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and myelokathexis) syndrome. This is the initial study of this concept and wi...
What is the current status of trial NCT01058993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01058993?
The interventions under investigation include: AMD3100 or plerixafor (DRUG).
Who is sponsoring clinical trial NCT01058993?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01058993's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia